MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2018 International Congress

    Mitochondrial phenotype related to the A30P alpha-synuclein mutation as a patient-derived cellular model of Parkinson’s disease

    B. Santos, P. Barbuti, P. Antony, J. Arias, A. Hummel, J. Schwamborn, R. Krüger (Belval, Luxembourg)

    Objective: Our study aims to perform detailed phenotyping of the A30P alpha-synuclein familial case of PD, allowing to identify underlying mechanisms of the disease that…
  • 2018 International Congress

    Nanoscale imaging reveals disorganization of the brain extracellular space in Lewy body-injected mice

    F. Soria, N. Danne, C. Paviolo, E. Doudnikoff, B. Dehay, L. Groc, L. Cognet, E. Bezard (Bordeaux, France)

    Objective: To explore the brain extracellular space and its matrix at a nanometric scale in a context of α-synuclein-induced neurodegeneration. Background: The extracellular space (ECS)…
  • 2018 International Congress

    Parkinson’s disease anxiety is associated with Lewy bodies in the Anterior Cingulate

    N. Fischer, J. Hinkle, K. Perepezko, G. Pontone (Baltimore, MD, USA)

    Objective: The goal of this study is to determine if there is an association between anxiety and the presence and regional distribution of Lewy bodies…
  • 2018 International Congress

    Development of a biomarker for Parkinson’s disease by measuring alpha-synuclein oligomers in cerebrospinal fluid with ultrasonication-induced amyloid fibril formation

    K. Kakuda, K. Ikenaka, K. Araki, Y. Kajiyama, M. So, H. Hayakawa, T. Omichi, K. Baba, K. Konaka, T. Tokuda, Y. Goto, H. Mochizuki (Suita, Japan)

    Objective: To establish a new technique quantifying misfolded alpha-synuclein (αSyn) oligomers in the CSF and to investigate their clinical - pathological significances in Parkinson’s disease…
  • 2018 International Congress

    Microarray analysis upon an synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease

    E. Tao (Guangzhou, China)

    Objective: To uncover new disease-associated genes and their relevant mechanisms in the pathogenetic process of neurodegenerative disorders, we carried out a gene microarray analysis based…
  • 2018 International Congress

    Cell and animal models lacking RAB39B show biochemical and behavioural phenotypes that model aspects of Parkinson’s disease

    Y. Gao, G. Wilson, S. Stephenson, K. Bozaoglu, M. Dottori, P. Thomas, P. Lockhart (Melbourne, Australia)

    Objective: To determine the pathogenic mechanisms underlying RAB39B-mediated Parkinson’s disease (PD). Background: PD is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the…
  • 2018 International Congress

    Effects of JN403, an α-7-nicotine-acetylcholine-receptor (α7-nAChR) agonist on human alpha-synuclein-mediated in vitro and in vivo models of Parkinson’s disease

    B. Lee, C. Noelker, W. Chiu, D. Feuerbach, L. Timmerman, W. Oertel (Marburg, Germany)

    Objective: To investigate whether JN403, a novel selective agonist of α-7-nicotine-acetylcholine-receptors (α7-nAChRs) can suppress inflammation and toxicity in human alpha-synuclein (αSyn) induced in vitro and…
  • 2018 International Congress

    Identification and analysis of differential miRNA in exosomes of dopaminergic neurons overexpressing α-synuclein

    Y. Liang, D. Lin, T. Zhou, D. Zheng (Guangzhou, China)

    Objective: The aim of this study was to compare the miRNA expression in secreted exosomes from dopaminergic neurons overexpressing α-synuclein with healthy neurons. Background: Exosomes,…
  • 2018 International Congress

    Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)

    L. Chahine, T. Beach, C. Coffey, C. Caspell-Garcia, C. Alder, G. Serrano, S. Mosovsky, T. Foroud, C. Linder, H. Riss, D. Ecklund, J. Seibyl, A. Mallya, V. Arnedo, L. Riley, K. Dave, D. Jennings, B. Mollenhauer (Pittsburgh, PA, USA)

    Objective: To characterize the distribution of alpha-synuclein (aSyn) pathology in multiple tissues and body fluids within the same Parkinson’s disease (PD) subjects and compared to…
  • 2018 International Congress

    Oral treatment with JNX3001 protects dopaminergic function in a non-human primate model of Parkinson’s disease alpha-synucleinopathy

    P. Howson, T. Johnston, J. Brotchie, M. Hill, J. Koprich (Toronto, ON, Canada)

    Objective: We evaluated the efficacy of JNX3001 in an aSyn-based macaque model with plasma exposures associated with efficacy in rodents. Background: Alpha-synuclein (aSyn) deposition is…
  • « Previous Page
  • 1
  • …
  • 56
  • 57
  • 58
  • 59
  • 60
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley